Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Allo-HSCT Regimen for Severe Aplastic Anemia
NCT06378060Phase 2Recruiting
- Sponsor
- Hematology Department, 920th Hospital
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by Hematology Department, 920th Hospital. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06378060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378060.